Record Details

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy

Hematology Reports

View Archive Info
Field Value
Authentication Code dc
Title Statement Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
Added Entry - Uncontrolled Name Zhenshu Xu; Division of Hematology and Oncology, New York Medical College, Valhalla, NY 10595.
Shundong Cang; Division of Hematology and Oncology, New York Medical College, Valhalla, NY 10595
Ting Yang; Department of Hematology, Institute of Hematology, Union Hospital, Fujian Medical University, Fuzhou
Delong Liu; Division of Hematology and Oncology, New York Medical College, Valhalla, NY
This work was partly supported by New York Medical College Blood Diseases Fund. Writing and editorial support were provided by Zoila Mora and Josh Collis, and funded by Bristol-Myers Squibb Co.
Uncontrolled Index Term Medicine; Hematology; Chronic Myeloid Leukemia
Chronic Myeloid Leukemia; Tyrosine Kinase Inhibitors
Summary, etc. Emerging evidence suggests that the three tyrosine kinase inhibitors currently approved for the treatment of patients with chronic myelogenous leukemia (CML) – imatinib, dasatinib, and nilotinib – have potential cardiotoxic effects. The mechanisms behind these events, and the relations between them, are largely unclear. For example, relative to dasatinib and nilotinib, severe congestive heart failure and left ventricular dysfunction are rare but prominent with imatinib treatment, particularly in patients receiving higher doses (>600 mg/day). In comparison with imatinib, prolongation of the QT interval is relatively common in patients treated with either dasatinib or nilotinib. In contrast to nilotinib, pericardial effusions are observed with both imatinib and dasatinib. It is suggested that these data, an evaluation of cardiac status, use of concomitant medications, and potential risk factors should be considered in the management of CML. 
Publication, Distribution, Etc. PAGEPress Publications
Electronic Location and Access application/pdf
Data Source Entry Hematology Reports; Vol 1, No 1 (2009); e4
Language Note en
Terms Governing Use and Reproduction Note <p>PAGEPress has chosen to apply the <a href="" target="_blank">Creative Commons Attribution License</a> (CCAL) to all manuscripts to be published. </p> <p>An Open Access Publication is one that meets the following two conditions:</p> <ol><li>The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li><li>A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li></ol> Authors who publish with this journal agree to the following terms: 1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. 3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).